KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash & Equivalents (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Cash & Equivalents for 8 consecutive years, with $167.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 15.95% year-over-year to $167.9 million, compared with a TTM value of $167.9 million through Dec 2025, up 15.95%, and an annual FY2025 reading of $167.9 million, up 15.95% over the prior year.
  • Cash & Equivalents was $167.9 million for Q4 2025 at Esperion Therapeutics, up from $92.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $226.6 million in Q1 2024 and bottomed at $82.2 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $147.7 million, with a median of $144.7 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents skyrocketed 76.01% in 2024, then crashed 54.54% in 2025.
  • Year by year, Cash & Equivalents stood at $208.9 million in 2021, then plummeted by 40.27% to $124.8 million in 2022, then plummeted by 34.08% to $82.2 million in 2023, then surged by 76.01% to $144.8 million in 2024, then grew by 15.95% to $167.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for ESPR at $167.9 million in Q4 2025, $92.4 million in Q3 2025, and $86.1 million in Q2 2025.